MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

Core Viewpoint - MediciNova, Inc. is actively engaging with investors at the upcoming DBC Conference, highlighting its focus on innovative treatments for serious neurological and metabolic disorders [1][2]. Company Overview - MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, primarily targeting the U.S. market [2]. - The company's leading programs include MN-166 (ibudilast) for various neurological disorders such as amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (MS), and MN-001 (tipelukast) for fibrotic and metabolic disorders like nonalcoholic fatty liver disease (NAFLD) [2]. Strategic Focus - MediciNova plans to advance its pipeline through a combination of investigator-sponsored clinical trials, government grants, self-funded trials, and strategic alliances to support the clinical development of its lead programs [2].